-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Teknova And Pluristyx Announce Strategic Collaboration To Commercialize PluriFreeze, Streamlining Cell Therapy Development

Benzinga·03/12/2025 06:41:22
Listen to the news

Alpha Teknova, Inc. and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze™ product line, a cryopreservative and cell wash media system intended for use by customers who are developing next generation allogeneic cell therapies. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading and safety-switch enabled iPSCs, and other innovative technologies designed to shorten the development lifecycle of tomorrow's cell therapies.

Through their developmen